Polarean Imaging plc (AIM: POLX), a provider of advanced Magnetic Resonance Imaging (MRI) for lung function, announced on Monday that it has signed its first distribution agreement with Sumtage Enterprise Company Limited for the distribution of its Xenon MRI platform in Taiwan.

This deal marks a significant step in expanding Polarean's international presence.

Polarean will collaborate with Sumtage to secure the necessary regulatory approvals for the commercial launch of its innovative Xenon MRI technology in Taiwan. Sumtage, a medical distributor with 30 years of experience, will provide ongoing support and maintenance services for the product.

Headquartered in Durham, NC, and London, UK, Polarean is revolutionising pulmonary medicine by offering non-invasive, radiation-free imaging solutions. Its flagship product, XENOVIEW, the first FDA-approved hyperpolarised Xenon MRI inhaled contrast agent, is designed to meet the needs of over 500 million patients globally suffering from chronic respiratory diseases.